Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition

PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Ryan, Meagan B., de la Cruz, Ferran Fece, Phat, Sarah, Myers, David T., Wong, Edmond, Shahzade, Heather A., Hong, Catriona B., Corcoran, Ryan B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/
https://ncbi.nlm.nih.gov/pubmed/31776128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk